Literature DB >> 8948358

Conformal irradiation of the prostate: estimating long-term rectal bleeding risk using dose-volume histograms.

A C Hartford1, A Niemierko, J A Adams, M M Urie, W U Shipley.   

Abstract

PURPOSE: Dose-volume histograms (DVHs) may be very useful tools for estimating probability of normal tissue complications (NTCP), but there is not yet an agreed upon method for their analysis. This study introduces a statistical method of aggregating and analyzing primary data from DVHs and associated outcomes. It explores the dose-volume relationship for NTCP of the rectum, using long-term data on rectal wall bleeding following prostatic irradiation. METHODS AND MATERIALS: Previously published data were reviewed and updated on 41 patients with Stages T3 and T4 prostatic carcinoma treated with photons followed by perineal proton boost, including dose-volume histograms (DVHs) of each patient's anterior rectal wall and data on the occurrence of postirradiation rectal bleeding (minimum FU > 4 years). Logistic regression was used to test whether some individual combination of dose and volume irradiated might best separate the DVHs into categories of high or low risk for rectal bleeding. Further analysis explored whether a group of such dose-volume combinations might be superior in predicting complication risk. These results were compared with results of the "critical volume model," a mathematical model based on assumptions of underlying radiobiological interactions.
RESULTS: Ten of the 128 tested dose-volume combinations proved to be "statistically significant combinations" (SSCs) distinguishing between bleeders (14 out of 41) and nonbleeders (27 out of 41), ranging contiguously between 60 CGE (Cobalt Gray Equivalent) to 70% of the anterior rectal wall and 75 CGE to 30%. Calculated odds ratios for each SSC were not significantly different across the individual SSCs; however, analysis combining SSCs allowed segregation of DVHs into three risk groups: low, moderate, and high. Estimates of probabilities of normal tissue complications (NTCPs) based on these risk groups correlated strongly with observed data (p = 0.003) and with biomathematical model-generated NTCPs.
CONCLUSIONS: There is a dose-volume relationship for rectal mucosal bleeding in the region between 60 and 75 CGE; therefore, efforts to spare rectal wall volume using improved treatment planning and delivery techniques are important. Stratifying dose-volume histograms (DVHs) into risk groups, as done in this study, represents a useful means of analyzing empirical data as a function of hetereogeneous dose distributions. Modeling efforts may extend these results to more heterogeneous treatment techniques. Such analysis of DVH data may allow practicing clinicians to better assess the risk of various treatments, fields, or doses, when caring for an individual patient.

Entities:  

Mesh:

Year:  1996        PMID: 8948358     DOI: 10.1016/s0360-3016(96)00366-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy.

Authors:  David L Schwartz; Katherine Hutcheson; Denise Barringer; Susan L Tucker; Merrill Kies; F Christopher Holsinger; K Kian Ang; William H Morrison; David I Rosenthal; Adam S Garden; Lei Dong; Jan S Lewin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-18       Impact factor: 7.038

2.  3-D Conformal radiotherapy of localized prostate cancer within an Austrian-German multicenter trial: a prospective study of patients' acceptance of the rectal balloon during treatment.

Authors:  Gregor Goldner; Hans Geinitz; Stefan Wachter; Gerd Becker; Frank Zimmermann; Natascha Wachter-Gerstner; Stefan Glocker; Regina Pötzi; Andre Wambersie; Michael Bamberg; Michael Molls; Horst Feldmann; Richard Pötter
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

3.  Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.

Authors:  Alexei Trofimov; Paul L Nguyen; John J Coen; Karen P Doppke; Robert J Schneider; Judith A Adams; Thomas R Bortfeld; Anthony L Zietman; Thomas F Delaney; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-21       Impact factor: 7.038

4.  Evaluation of late rectal toxicity after conformal radiotherapy for prostate cancer: a comparison between dose-volume constraints and NTCP use.

Authors:  Raffaella Cambria; Barbara A Jereczek-Fossa; Federica Cattani; Cristina Garibaldi; Dario Zerini; Cristiana Fodor; Flavia Serafini; Guido Pedroli; Roberto Orecchia
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

5.  Distinct effects of rectum delineation methods in 3D-conformal vs. IMRT treatment planning of prostate cancer.

Authors:  Matthias Guckenberger; Jürgen Meyer; Kurt Baier; Dirk Vordermark; Michael Flentje
Journal:  Radiat Oncol       Date:  2006-09-06       Impact factor: 3.481

6.  Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT.

Authors:  L Wang; B Movsas; R Jacob; E Fourkal; L Chen; R Price; S Feigenberg; A Konski; A Pollack; C Ma
Journal:  J Appl Clin Med Phys       Date:  2004-04-01       Impact factor: 2.102

Review 7.  Big Data Analytics for Prostate Radiotherapy.

Authors:  James Coates; Luis Souhami; Issam El Naqa
Journal:  Front Oncol       Date:  2016-06-14       Impact factor: 6.244

8.  Development of a treatment planning protocol for prostate treatments using intensity modulated radiotherapy.

Authors:  G A Ezzell; S E Schild; W W Wong
Journal:  J Appl Clin Med Phys       Date:  2001       Impact factor: 2.102

9.  Optimization of photon beam energy in aperture-based inverse planning.

Authors:  Jason St-Hilaire; Caroline Sévigny; Frédéric Beaulieu; Luc Gingras; Daniel Tremblay; Luc Beaulieu
Journal:  J Appl Clin Med Phys       Date:  2009-09-03       Impact factor: 2.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.